Phase 2
Completed N=131
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
Venous Thromboembolism · Deep Venous Thrombosis · Surgery
Source: ClinicalTrials.gov NCT03251963 ↗
Enrolled (actual)
131
Serious AEs
0.8%
Results posted
Jul 2020
Primary outcomePrimary: Number of Patients With in Range Initial Peak Xa Level — 27; 27 Participants
Summary
The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With in Range Initial Peak Xa Level |
27; 27 | — |
| SECONDARY Number of Participants With Venous Thromboembolism Events or Death |
1; 0 | — |
| SECONDARY Number of Participants With Bleeding Events |
1; 3 | — |
Eligibility Criteria
Inclusion Criteria
- receiving Video-Assisted Thoracoscopic Surgery
- able to have Enoxaparin initiated within 8 hours after procedure
Exclusion Criteria
- Contraindication to use of enoxaparin
- Intracranial bleeding/stroke
- Hematoma or bleeding disorder
- Heparin-induced thrombocytopenia positive
- Creatinine clearance less than or equal to 30 mL/min
- Serum creatinine greater than 1.6 mg/dL
- Epidural catheter
Data sourced from ClinicalTrials.gov (NCT03251963). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.